Journal article
Can butyrate prevent colon cancer? The AusFAP study: A randomised, crossover clinical trial
J Clarke, A Boussioutas, B Flanders, T Lockett, K Harrap, I Saunders, P Lynch, M Appleyard, A Spigelman, D Cameron, F Macrae
Contemporary Clinical Trials Communications | ELSEVIER INC | Published : 2023
Abstract
Increased colonic butyrate from microbial fermentation of fibre may protect from colorectal cancer (CRC). Dietary butyrylated high amylose maize starch (HAMSB) delivers butyrate to the large bowel. The objective of this clinical trial (AusFAP) is to evaluate potential chemoprotective effects of HAMSB on polyposis in individuals with a genetic form of colon cancer, Familial Adenomatous Polyposis (FAP). The study is a multi-site, double blind, randomised, placebo-controlled crossover trial undertaken at major hospitals in Australia. After a baseline endoscopy participants consume either 40g/day of HAMSB or placebo (low amylose maize) starch for 26 weeks. After another endoscopic examination pa..
View full abstractGrants
Funding Acknowledgements
This work (Application APP1031108) is supported by the Cancer Councils of New South Wales, Victoria, Queensland and South Australia. None of these funding organisations are involved in study design or collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the article for publication. Additional support to complete the study is being provided by Royal Melbourne Hospital, Victoria and CSIRO Health and Biosecurity, Australia.